1ZOLTAN V, JANET F, WILLIAM C D. Recobinant DNA technology in the treatment of diabetes: insulin analogs [ J ]. Endocr Rev, 2001, 22 (5) :706-717.
2COPPOLINO R, COPPOLINO S, VILLARI V. Study of the aggregation of insulin glargine by light scattering [ J ]. J Pharm Sci, 2006, 95 (5) :1029-1034.
3HEINEMANN L, LINKESCHOVA R, RAVE K, et al. Timeaction profile of the long-acting insulin analog insulin glargine ( HOEgO1 ) in comparison with those of NPH insulin and placebo [J]. Diabetes Care, 2000, 23 (5) :644-649.
4PAYAM M, ABDOLHOSSEIN R N, HOSNIEH T. A rapid and sensitive method for simultaneous determination of insulin and A21-desamido insulin by high-performance liquid chromatography [J]. J Pharm BiornedAnal, 2003, 33 (1) :45-51.
5BRANGE J, LANGKJAER L, HAVELUND S, et al. Chemical stability of insuli. 1. Hydrolytic degradation during storage of pharmaceutical preparations[ J ]. Pharm Res, 1992, 9 (6) :715- 726.
6Ch. P (2005) Vol Ⅱ(中国药典2005年版,二部)[S].2005:Appendix33.
7ZHOU Y, OTrENS M, HANSEN E, et al. Human insulin and desamieo human insulin isotherms in ethanol-water reversed phase systems[J]. J Chromatogr A, 2004, 1061 (2) :141-148.
8FRANK B H, CHANCE R E. Therapeutic agents produced by genetic engineering [ C ]. 1 st ed. Symposium, Group: Toulouse- Labege :Sanofi Group, 1985 : 138-142.
9CHANCE R, GLAZER N, WISHNER K. Biopharmaceuticals [ M ]. 1st Dordrednt : Kluwer Academic Publishers, 1999 : 149- 151.
10JARS M U, HVASS A, WAABEN D. Insulin aspart (AspB28 human insulin ) derivatives formed in pharmaceutical solutions [J]. Pharm Res, 2002, 19 (5) :621-628.
